PMID- 28978166
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 40
DP  - 2017 Sep 15
TI  - Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.
PG  - 68899-68915
LID - 10.18632/oncotarget.20324 [doi]
AB  - Pancreatic cancer (PC) is an aggressive disease with high mortality rates, 
      however, there is no blood test for early detection and diagnosis of this 
      disease. Several research groups have reported on metabolomics based clinical 
      investigations to identify biomarkers of PC, however there is a lack of a 
      centralized metabolite biomarker repository that can be used for meta-analysis 
      and biomarker validation. Furthermore, since the incidence of PC is associated 
      with metabolic syndrome and Type 2 diabetes mellitus (T2DM), there is a need to 
      uncouple these common metabolic dysregulations that may otherwise diminish the 
      clinical utility of metabolomic biosignatures. Here, we attempted to externally 
      replicate proposed metabolite biomarkers of PC reported by several other groups 
      in an independent group of PC subjects. Our study design included a T2DM cohort 
      that was used as a non-cancer control and a separate cohort diagnosed with 
      colorectal cancer (CRC), as a cancer disease control to eliminate possible 
      generic biomarkers of cancer. We used targeted mass spectrometry for quantitation 
      of literature-curated metabolite markers and identified a biomarker panel that 
      discriminates between normal controls (NC) and PC patients with high accuracy. 
      Further evaluation of our model with CRC, however, showed a drop in specificity 
      for the PC biomarker panel. Taken together, our study underscores the need for a 
      more robust study design for cancer biomarker studies so as to maximize the 
      translational value and clinical implementation.
FAU - Mehta, Khyati Y
AU  - Mehta KY
AD  - Department of Oncology, Georgetown University Medical Center, Washington, DC, 
      United States of America.
FAU - Wu, Hung-Jen
AU  - Wu HJ
AD  - Department of Biochemistry and Molecular and Cellular Biology, Georgetown 
      University Medical Center, Washington, DC, United States of America.
FAU - Menon, Smrithi S
AU  - Menon SS
AD  - Department of Oncology, Georgetown University Medical Center, Washington, DC, 
      United States of America.
FAU - Fallah, Yassi
AU  - Fallah Y
AD  - Department of Oncology, Georgetown University Medical Center, Washington, DC, 
      United States of America.
FAU - Zhong, Xiaogang
AU  - Zhong X
AD  - Department of Biostatistics Bioinformatics and Biomathematics, Georgetown 
      University, Washington, DC, United States of America.
FAU - Rizk, Nasser
AU  - Rizk N
AD  - Department of Health Sciences, Qatar University, Doha, Qatar.
FAU - Unger, Keith
AU  - Unger K
AD  - Lombardi Comprehensive Cancer Center, Med-Star Georgetown University Hospital, 
      Washington, DC, United States of America.
FAU - Mapstone, Mark
AU  - Mapstone M
AD  - Department of Neurology, University of California, Irvine, CA, United States of 
      America.
FAU - Fiandaca, Massimo S
AU  - Fiandaca MS
AD  - Department of Neurology, University of California, Irvine, CA, United States of 
      America.
AD  - Department of Neurological Surgery, University of California, Irvine, CA, United 
      States of America.
FAU - Federoff, Howard J
AU  - Federoff HJ
AD  - Department of Neurology, University of California, Irvine, CA, United States of 
      America.
FAU - Cheema, Amrita K
AU  - Cheema AK
AD  - Department of Oncology, Georgetown University Medical Center, Washington, DC, 
      United States of America.
AD  - Department of Biochemistry and Molecular and Cellular Biology, Georgetown 
      University Medical Center, Washington, DC, United States of America.
LA  - eng
GR  - P30 CA051008/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170818
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5620306
OTO - NOTNLM
OT  - biomarkers
OT  - metabolomics
OT  - pancreatic cancer
COIS- CONFLICTS OF INTEREST The authors declare no competing conflicts of interest.
EDAT- 2017/10/06 06:00
MHDA- 2017/10/06 06:01
PMCR- 2017/09/15
CRDT- 2017/10/06 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/08/04 00:00 [accepted]
PHST- 2017/10/06 06:00 [entrez]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2017/10/06 06:01 [medline]
PHST- 2017/09/15 00:00 [pmc-release]
AID - 20324 [pii]
AID - 10.18632/oncotarget.20324 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 18;8(40):68899-68915. doi: 10.18632/oncotarget.20324. 
      eCollection 2017 Sep 15.